Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 5, 2008, Pages 591-594

  Horwitz, Mitchell E ^a   Morris, Ashley ^a   Gasparetto, Cristina ^a   Sullivan, Keith ^a   Long, Gwynn ^a   Chute, John ^a   Rizzieri, David ^a   McPherson, Jackie ^a   Chao, Nelson ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Busfulfan; Dual umbilical cord blood; Fludarabine

Indexed keywords

BUSULFAN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CRYOPRESERVATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RELIABILITY;

ADULT; BUSULFAN; CELL COUNT; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TREATMENT FAILURE; VIDARABINE;

EID: 41849089390     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.016     Document Type: Article

References (14)

1. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
2. Laughlin M., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
3. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
4. Ballen K.K., Spitzer T.R., Yeap B.Y., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 13 (2007) 82-89
5. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110 (2007) 3064-3070
6. Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr. 987;416:426-432.
7. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., Miller J.S., and Wagner J.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
8. Peters W.P., Henner W.D., Grochow L.B., et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47 (1987) 6402-6406
9. Gandhi V., and Plunkett W. Cellular and clinical pharmacology of fludarabine. Clinl Pharmacokinet 41 (2002) 93-103
10. Nilsson C., Forsman J., Hassan Z., et al. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Exp Hematol 33 (2005) 380-387
11. Pratt W., Ruddon R., Ensminger W., and Maybaum J. The Anticancer Drugs. 2nd ed (1994), Oxford University Press, New York 108-109, 128
12. Sikic B. In: Craig C.R., and Stitzel R.E. (Eds). Antineoplastic Agents. 3rd ed. Modern Pharmacology (1990), Little, Brown and Co.,, Boston 787 796-797
13. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 (2006) 2874-2880
14. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947